<DOC>
	<DOCNO>NCT02294851</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , single ascend dose escalation , safety , tolerability , PK , PD immunogenicity study BMS-986168 administer intravenous infusion healthy subject .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled , Single Ascending Dose Study Intravenously Administered BMS-986168 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Tauopathies</mesh_term>
	<criteria>Healthy male female subject , clinically significant deviation normal medical history , physical examination , ECGs clinical laboratory determination . Body Mass Index ( BMI ) 18.530 kg/m^2 , inclusive . BMI=weight ( kg ) / [ height ( ) ] ^2 . Males Females , childbearing potential , age 21 65 year , inclusive . Female subject must document proof childbearing potential . Male subject must willing use effective birth control refrain sperm donation entire study 200 day dose complete . Women childbearing potential breastfeeding . Any significant acute chronic medical illness . Any history cancer within 5 year enrollment . Any major surgery within 4 week study drug administration . Donation blood serum &gt; 500 mL blood bank clinical study ( except screen visit ) within 3 month study drug administration . Participation clinical study ( except screen visit ) within 4 week ( 5 half life , whichever long ) , study drug administration . Inability venipunctured and/or tolerate venous access . Has smoke use tobacco product within 6 month prior study drug administration . Recent ( within 6 month study drug administration ) drug alcohol abuse define DSM IV , Diagnostic Criteria Drug Alcohol Abuse</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>